WuXi AppTec Closes at IPO Price on First Day of Hong Kong Trading

TRENDING: ByteDance Plans Subscriptions for AI Chatbot Doubao; U.S. Chipmaker Onsemi Reaffirms Commitment to China as Demand Rises From EV Shift

LATEST: ByteDance Plans Subscriptions for AI Chatbot Doubao; U.S. Chipmaker Onsemi Reaffirms Commitment to China as Demand Rises From EV Shift; U.S. Moves to Block Chinese Labs From Certifying Electronics; Cover Story: AI Drives Markets as Valuations Race Ahead of Earnings; Insta360 Profit Falls as R&D Surge Meets Rising DJI Competition; Beijing to Impose Sweeping Drone Sales Ban From May 1; Lightelligence Sets Record IPO Gain with 383% Surge on Hong Kong Debut; Robot Era Raises Over $200 Million as Humanoid Robot Race Heats Up; DeepSeek Launches New AI Model as Funding Rumors Spread; Tencent Unveils New AI Model to Close Gap With Rivals; DJI Enters Heavy-Lift Drone Market With 200-Kilogram Payload Models; Apple Supplier Dongshan Precision Rallies on AI-Driven Demand; Horizon Robotics Unveils 5-Nanometer Integrated Auto Chip; In Depth: China’s AI Hiring Boom Belies a Struggling Job Market; China Unveils AI-Driven Plan to Build $14 Trillion Service Sector by 2030; X Square Robot Raises New Funds, Targets Home Trials by May; Computing Shortage Forces Chinese AI Firms to Ration Services; Moonshot AI Launches New Model With Improved Coding and Agent Capabilities; Chinese Firm Uses Employee Data to Build AI Worker, Stoking Job Security Debate; China’s Sunrise Raises Over $140 Million for AI Inference Chip Push

By Charlotte Yang / Dec 13, 2018 05:17 PM / Business & Tech

WuXi AppTech executives at the Shanghai exchange in May. Photo: VCG

Hong Kong shares of biotech superstar WuXi AppTec began their first day of trading Thursday at HK$67, and closed at their IPO price of HK$68.

WuXi AppTec is among an emerging group of fast-growing Chinese biotech firms that are tapping financial markets at home and abroad. But unlike many of its peers, WuXi AppTec is profitable, as others lose money while their drugs go through clinical trials and await regulatory approval.

In May, the firm surged 44% on its Shanghai debut, rising from an IPO price of 21.6 yuan ($3.14) to 31.1 yuan and hitting Shanghai’s daily increase limit for newly-listed shares.

Share this article

Open WeChat and scan the QR code